July 2006
Research funding controversy
by Robert H. Blanks PhD, President, RCS
>>> More than half of
all medical studies funded by for‑profit sources
According to a recent
article in the Journal of the American Medical Society,[1],
biomedical research funding in the
United States has doubled, when
adjusted for inflation, from $37.1 billion in 1994 to $94.3 billion in 2003.
Among the current
funding sources, the majority (57%) is from for‑profit commercial sources.
The National Institutes of Health accounts for only 28% and private sources
(foundations, voluntary health organizations, and free‑standing research
institutes) the remaining 15%.
As we well know, only a
small fraction of this amount has found its way into chiropractic. That's
why it's important to understand more about the funding base in biomedicine.
If we can figure out where the medical industry finds the money for its
research, we can apply the same economic model to chiropractic.
No matter what
differences chiropractors have, they can all agree on one thing:
chiropractic needs more research funding to initiate clinical trials across
a wide variety of clinical conditions, and to evaluate the adjustment in
non‑condition based areas such as quality of life and wellness.
So far, the funding has
not come from government grants. Of the 15,000 plus clinical trials
currently registered with the US National Institutes of Health (http://www.clinicaltrials.gov),
only five are chiropractic and these have evaluated only musculoskeletal
issues (low back pain, three trials; headaches, one trial, and Temporal
Mandibular Joint pain, one trial).
So, point one is
that we need money to conduct valid, scientific research.
Point two
is also one we can all agree upon. We need to tap into a variety of sources
for research funding ‑‑ commercial, federal and private entities (college,
non‑profit organizations, etc.).
Naturally, accepting
funding from different sources can raise many thorny ethical issues. The
American Medical Association's Council on Scientific Affairs, for instance,
concluded that "studies with positive findings are more likely to be
published than studies with negative or null results, and an association
exists between pharmaceutical industry sponsorship of clinical research and
publication of results favoring the sponsor's products."
Further, they warned
that "When control lies with the commercial rather than academic or public
sector, bias can also envelop the process through the trial design...
Outcome bias can result from the use of unreliable methods or instruments,
as well as inadequate sample size or comparison groups."
These conclusions were
based on a literature search of more than 2,000 articles published between
1985 and 2003. [2]
Similar findings,
published in the American Journal of Psychiatry, were obtained from
an evaluation of psychiatric clinical trials, where there was a greater
likelihood of reporting a drug to be superior to placebo when the authors
reported receiving funding from the pharmaceutical company or other
interested party. As many as 60% of the contributing authors surveyed among
the 397 trials reviewed reported financial conflict of interest!
In an even larger study
of general medical trials, between 30‑50% of authors reported conflict of
financial interest. In this survey of 162 randomized, double‑blind,
placebo‑controlled studies (as reported in Psychiatric News, Oct. 21,
2005) studies conducted by researchers with conflicts of interest were 4.9
times more likely to find positive results from the intervention.
What's more, being
funded by a university or federal grant would insure the absence of study
bias doesn't solve the problem. Research results can be substantially biased
from academic and institutional pressures and even by the media.
In a now‑classic
article entitled, "On the folly of rewarding A while hoping for B," Steven
Kerr argues that there is always explicit and implicit bias by
investigators and their institutions in conducting research. [3]
Such unconventional
conflict of interest arises in academics when faculty members are expected
by the organization to be devoted teachers, yet they are primarily rewarded
for activities such as research and research publication.
The dichotomy between
desired and actual results can create conflicting interests between
investigators, the institution and the public welfare. [4]
Kerr and others argue
that this dichotomy of interests create conflicts of interest
even in the most traditional research environment of the university, and in
particular within not‑for‑profit academic health centers, where a large
proportion of clinical trails are being conducted [5].
Research grants and
contracts are major sources of revenue for institutions and reward
individual investigator efforts more than group efforts. These conflicts
between scientific opportunities and public needs are not necessarily bad
and can be mitigated by careful balancing of competing priorities [6].
Clearly, all research
is subject to bias stemming from funding source, as well as other
well‑defined issues such as poor experimental design, difficulties with
interpretation, and the media treatment of the published findings.
Biomedicine lives in a
world of carefully managed conflicts of interest. Researchers have learned
to reduce the risk of experimental bias because of the funding source by
disclosing the source and by balancing the risk with the possible benefit to
society and the patient through discovery of new drugs and technology.
In chiropractic, the
research community hasn't yet learned to deal with those inherent risks as
well as the medical industry. It still tries to rely solely on government
grants and what little money can be raised by the colleges. Even top
research leaders admit this isn't nearly enough to conduct the type of
research the profession needs.
Yet, there is great
resistance to tapping into the potential funding from private‑sector
research. Such enterprises are deemed sullied by their for‑profit status,
even if a vast majority of that profit is reinvested into building the
research infra‑structure.
In one way, this is
understandable, since chiropractic has to be squeaky clean in order to avoid
criticisms from the medical arena. That's why it's important for any
research program, particularly those conducted by for‑profit or private
research entities, to be reviewed and approved by an independent
Institutional Review Board (IRB). IRBs routinely investigate potential
conflict of interest issues, including those arising from funding as well as
institutional and investigational bias.
Once the IRB has given
a clean bill of health to the program, the fear of conflict of interest
should be minimized. After all, the chiropractic profession has a long and
proud history of private enterprise to prove that profit can co‑exist with
quality. All chiropractic techniques were developed by private, for‑profit
companies or entrepreneurial individuals and even chiropractic colleges make
profits and pay salaries to their administrators, instructors and
researchers.
References
1. Moses III, H, Dorsey
ER, Matheson DHM, "Financial Anatomy of Biomedical Research." JAMA
2005 294:11, 1333‑1342.
2. "Influence of
Funding Source on Outcome, Validity, and Reliability of Pharmaceutical
Research" posted at presented as CSA Report 10 at the 2004 AMA Annual
Meeting.
3. "On the folly of
rewarding A while hoping for B," by Steven Kerr.
Academy of Management Journal,
18(4): 769‑783.
4. "Conflicts of
interest in translational research," Parks MR, Disis ML. J Transl Med.
2004;2:28(10), 1479‑5xx
5. "The not‑for‑profit
form and translational research: Kerr revisited?" Joiner KA, J Transl Med
2005 Apr 10.1186:1479‑5876‑3‑19.
6. "Scientific
opportunities and public needs: improving the priority setting and public
input at the National Institutes of Health, Washington, DC, Institutes of
Medicine"; National Academy Press, 1998.
(RCS co‑founder and
President Dr. Robert Blanks is Professor in the Department of Biomedical
Sciences at Florida Atlantic University and a past Professor of Anatomy and
Neurobiology at the University of California, Irvine. Prior to this he spent
two years at the Max Planck Institute for Brain Research in Frankfurt,
Germany and two years in the Department of Anatomy at Harvard Medical
School. Dr. Blanks is on the Advisory Board of the International Spinal
Health Institute, is a Board Member of the Council on Chiropractic Practice
and is actively involved in chiropractic research. To learn more about
health outcomes research and RCS, call 800‑909‑1354 or 480‑303‑1694.)